NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.
The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.
Foundation Medicine will receive an upfront payment from Eisai and is eligible for future diagnostic rights. Further terms of the alliance were not disclosed.
"This collaboration represents the continued advancement of our partnership strategy as we gain greater understanding into the key alterations driving tumor growth," Foundation Medicine President and CEO Michael Pellini said in a statement. "By using our comprehensive genomic profile to inform trial enrollment and outcomes analysis, Eisai can reveal the genomic drivers of an individual patient's disease and may be able to more rapidly advance effective targeted treatments for cancer."
The deal with Eisai is the latest in a string for Foundation Medicine, which has inked collaborations with Array BioPharma, N-of-One, Novartis, Clovis, and Johnson & Johnson.
Last month the firm raised $42.5 million in a Series B round of financing.